Zacks Investment Research
15 Jul 2026, 15:51 UTC · 2h ago
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
15 Jul 2026, 15:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Johnson & Johnson's Q2 2026 adjusted earnings per share were $2.90, beating the Zacks Consensus Estimate of $2.84. — Earnings beats typically drive positive short-term price action as they signal stronger-than-expected profitability.
+0.40J&J's total sales for the quarter reached $25.3 billion, slightly exceeding the Zacks Consensus Estimate of $25.2 billion. — Revenue growth and a beat on top-line expectations indicate steady demand and operational health.
+0.30Worldwide oncology sales grew 17.3% to $7.41 billion, driven largely by an 18.9% increase in Darzalex sales to $4.21 billion. — Strong growth in a high-margin, critical business segment like oncology provides long-term valuation support.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Innovative Medicine sales rose 7.8% to $16.38 billion, beating estimates and supported by growth in new drugs such as Carvykti and Tecvayli. — Success of new pipeline products offsets the decline of older drugs and ensures future revenue streams.
+0.20Which stocks this story touches
The company beat earnings and sales estimates for the second quarter of 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
33m ago
